The mysterious pathways of cardiac myxomas: a review of histogenesis, pathogenesis and pathology

被引:48
作者
Di Vito, Anna [1 ]
Mignogna, Chiara [2 ]
Donato, Giuseppe [2 ]
机构
[1] Univ Catanzaro Magna Graecia, Dept Clin & Expt Med, Pathol Unit, Sch Med, I-88100 Catanzaro, Italy
[2] Univ Catanzaro Magna Graecia, Dept Hlth Sci, Pathol Unit, Sch Med, I-88100 Catanzaro, Italy
关键词
cardiac myxoma; epithelial-mesenchymal transition; extracellular matrix; periostin; tenascin; LEFT ATRIAL-MYXOMA; EMBRYONIC STEM-CELLS; SMOOTH-MUSCLE; GROWTH-FACTOR; PRICHARDS STRUCTURES; PROGENITOR CELLS; FOSSA OVALIS; HEART-VALVES; EXPRESSION; PRKAR1A;
D O I
10.1111/his.12531
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cardiac myxoma is the most common benign cardiac tumour, localized generally in the left atrium. The majority of cardiac myxomas occur sporadically, while a relatively small proportion of cases develop as a part of Carney complex syndrome. Currently, the histogenesis of myxoma is poorly understood; however, the mesenchymal and endothelial properties of myxoma cells suggest that a clearer understanding of tumour origins can be achieved through a detailed investigation of heart development and endocardial histogenesis. Growing evidence appears to indicate the reactivated expression in cardiac myxoma of genes encoding heart precursor markers, although the exact mechanisms have not yet been described. In this paper we review the most recent scientific literature concerning cardiac embryology and relate this to recent advances in our understanding of the histogenesis of cardiac myxoma. Moreover, given that much of the literature regarding myxoma is of single case reports, we review progress in our knowledge of the pathology and pathogenesis of this condition.
引用
收藏
页码:321 / 332
页数:12
相关论文
共 128 条
  • [1] Acebo E, 2001, HISTOL HISTOPATHOL, V16, P1031, DOI 10.14670/HH-16.1031
  • [2] Prichard's structures of the fossa ovalis are not histogenetically related to cardiac myxoma
    Acebo, E
    Val-Bernal, JF
    Gómez-Román, JJ
    [J]. HISTOPATHOLOGY, 2001, 39 (05) : 529 - 535
  • [3] Acikel Sadik, 2012, Cardiovasc Pathol, V21, pe15, DOI 10.1016/j.carpath.2011.01.006
  • [4] ALDRIDGE HE, 1960, BRIT HEART J, V22, P189
  • [5] Amano Jun, 2003, Ann Thorac Cardiovasc Surg, V9, P215
  • [6] Badrisyah I, 2012, Med J Malaysia, V67, P613
  • [7] Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma
    Barh, Debmalya
    Kumar, Anil
    Chatterjee, Suvro
    Liloglou, Triantafillos
    [J]. CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 705 - 716
  • [8] Bartoloni Giovanni, 2013, Cardiovasc Pathol, V22, pe5, DOI 10.1016/j.carpath.2012.08.002
  • [9] Mucin-producing adenocarcinoma arising in an atrial myxoma
    Berger, Martin D.
    Schneider, Jakob
    Ballmer, Peter E.
    Eckhardt, Boris P.
    Dommann-Scherrer, Corina
    [J]. ANNALS OF DIAGNOSTIC PATHOLOGY, 2013, 17 (01) : 104 - 107
  • [10] Calretinin is essential for mesothelioma cell growth/survival in vitro: A potential new target for malignant mesothelioma therapy?
    Blum, Walter
    Schwaller, Beat
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (09) : 2077 - 2088